cdm85,True,2019-05-29 14:51:00,78.1,OMER Some more about Jakafi from INCY and similarities with Narsoplimab Jakafi was also moved directly from P2 to NDA granted priority review and later approval Very similar path as Narsoplimab is following from P2 to BLA GD aint kidding seekingalphacompr1719797 INCYFDA Grants Priority Review for Ruxolitinib Jakafi seekingalphacompr1731181 INCY
VladoSykora,,2019-05-29 11:00:00,79.25,Some Recent Upgrated NASDAQ100 AMAT LRCX VRTX DLTR INCYsource finscreener
Brice33,False,2019-05-29 10:21:00,79.736,COG INCY 4
